MMP9 and colitis: Importantly, a humanized MMP9 antibody (andecaliximab) has reached advanced clinical trials for the treatment of colitis (ClinicalTrials.gov: NCT02405442) [139, 140] and alimentary tract cancer (ClinicalTrials.gov: NCT01803282) [141, 142]; hence, it may also be repurposed for CIPN [143].